Jens Meiler Archives
Study reveals need for matching targeted therapies with EGFR subtypes
Jul. 28, 2022—A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.
VUMC’s Knollman, Ware among new AAAS Fellows
Feb. 2, 2022—Vanderbilt's Ware, Knollman among new American Association for the Advancement of Science Fellows.
Personalized Structural Biology aids cancer treatment decisions
Apr. 8, 2021—Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.
Study reframes approach to targeted therapy resistance
Apr. 11, 2019—When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.
Designing antibodies to fight the flu
Jan. 31, 2019—Vanderbilt investigators said their work shows that computational design can improve the ability of naturally occurring antibodies to recognize different flu strains and may hasten the development of more effective flu therapies and vaccines.
Transcription factor evolution
Aug. 11, 2016—Vanderbilt researchers have discovered a novel model of evolution for factors that control gene expression.
‘Young Scientist’ showcases high schoolers’ research at Vanderbilt
Jun. 2, 2016—High school students performing advanced research at Vanderbilt have the opportunity to share their findings with the scientific community through a journal of their own.
Potent HIV antibodies suggest new vaccine development approach
Apr. 7, 2016—It’s been known for some time that the immune system can produce antibodies capable of “neutralizing” HIV, and stopping the AIDS-causing virus dead in its tracks.
Dynamics of a drug resistance transporter
Feb. 5, 2016—Vanderbilt investigators are exploring the shape changes in a multidrug transporter to understand the mechanisms of antibacterial resistance.
‘Redesigned’ antibodies may control HIV: study
May. 21, 2015—With the help of a computer program called “Rosetta,” researchers at Vanderbilt University have “redesigned” an antibody that has increased potency and can neutralize more strains of the AIDS-causing human immunodeficiency virus (HIV) than can any known natural antibody.
VU lands $9 million NIH grant to design better flu vaccines
May. 15, 2015—Vanderbilt University researchers have received a five-year, $9 million grant from the National Institutes of Health (NIH) to design more effective flu vaccines and novel antibody therapies.
Members named to Academic Strategic Plan committees
Oct. 27, 2014—Two committees tasked with fleshing out key initiatives in Vanderbilt’s Academic Strategic Plan are now staffed and ready to begin work.
